Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 3U01DA013636 | U.S. NIH Grant/Contract | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Institute on Drug Abuse (NIDA) | NIH |
| Laura and John Arnold Foundation | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to determine which of three approaches started in jail is more effective in treating opioid use disorder: (1) methadone treatment without counseling (termed interim methadone) coupled with case management (termed patient navigation); (2) interim methadone without patient navigation; (3) or an enhanced treatment as usual including opioid detoxification, overdose prevention and drug treatment information and referral.
This study is part of the NIDA "Studies of Medication for Addiction Treatment in Correctional Settings (SOMATICS)" U01 Collaborative. Our distinct NIH-funded study at Friends Research Institute has been aligned with two other jail-based opioid treatment studies conducted by researchers at New York University (NYU) and at University of California Los Angeles (UCLA). SOMATICS seeks to harmonize assessments and interventions across the three research centers (RCs) and the three independent studies in order to leverage power, sample size, and increase the generalizability of findings. Each of the RCs in the SOMATICS cooperative will conduct their own individual trial, sharing one study arm with another RC, and several core assessments across all sites. The SOMATICS collaborative will have a common Statistical Analysis Plan and Data and Safety Monitoring Plan (DSMP) including a single DSMB. The collaborative primary and secondary outcomes across all sites are listed below:
Collaborative Primary Outcome Measure:
1. DSM-5 Opioid Use Disorder Diagnosis during the 30 days prior to the 6 months post-release follow-up assessment: Measured by: modified World Mental Health Composite International Diagnostic Interview.
Collaborative Secondary Outcome Measures:
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Methadone plus Patient Navigation | Experimental | Participants will begin methadone treatment during detention and will have a patient navigator for up to 3 months post-release from detention. |
|
| Methadone | Experimental | Participants will begin methadone during detention. |
|
| Enhanced Treatment as Usual | Active Comparator | Participants will receive opioid detoxification during detention, as well as drug abuse education, overdose prevention education, and referral to drug abuse treatment and overdose prevention services in the community. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Methadone | Drug | Interim methadone treatment (methadone without routine counseling) will be provided in jail. Methadone treatment with counseling will be continued in the community. |
| Measure | Description | Time Frame |
|---|---|---|
| Predicted Probability Derived From the Generalized Linear Mixed Model of Opioid Urine Test Positive Results Over Time | Predicted probability derived from the generalized linear mixed model opioid positive urine tests (0= negative; 1- positive) for heroin, oxycodone, methadone, or buprenorphine -- excluding the latter two positives when they results from prescribed medications to treat opioid use disorder) | 1, 3, 6, and 12 months post-release from incarceration |
| Predicted Probability Derived From the General Linear Mixed Model of Entry Into Treatment for Opioid Use Disorder on the Methadone Treatment Exposure Form | Predicted probability derived from the general linear mixed model of self-reported entry into treatment for opioid use disorder following release from incarceration and being in treatment 30 days post-release (0= no entry in treatment; 1= entry in treatment). | 30 days post-release from incarceration |
| Measure | Description | Time Frame |
|---|---|---|
| Predicted Probability Derived From Generalized Linear Mixed Model of Meeting Opioid Use Disorder Criteria as Determined by the Modified Composite International Diagnostic Interview (CIDI) | Predicted probability derived from the Generalized Linear Mixed Model of meeting the Data and Statistical Manual - 5 criteria for Opioid Use Disorder in response to modified CIDI interview (0= does not meet criteria; 1= meets criteria). |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Baltimore City Detention Center | Baltimore | Maryland | 21202 | United States |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 33196937 | Derived | Mitchell MM, Kelly SM, O'Grady KE, Jaffe JH, Mitchell SG, Schwartz RP. HIV-Risk Behavior Among Adults with Opioid Use Disorder During 12 Months Following Pre-trial Detention: Results from a Randomized Trial of Methadone Treatment. AIDS Behav. 2021 Apr;25(4):1247-1256. doi: 10.1007/s10461-020-03090-y. Epub 2020 Nov 16. | |
| 33187759 | Derived | Schwartz RP, Kelly SM, Mitchell SG, O'Grady KE, Duren T, Sharma A, Gryczynski J, Jaffe JH. Randomized trial of methadone treatment of arrestees: 24-month post-release outcomes. Drug Alcohol Depend. 2021 Jan 1;218:108392. doi: 10.1016/j.drugalcdep.2020.108392. Epub 2020 Nov 2. |
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Methadone Plus Patient Navigation | Participants will begin methadone treatment during detention and will have a patient navigator for up to 3 months post-release from detention. Methadone: Interim methadone treatment (methadone without routine counseling) will be provided in jail. Methadone treatment with counseling will be continued in the community. Patient Navigation: A patient navigator will assist the participant for the first three months after release from jail to enter and remain in methadone treatment in the community. |
| FG001 | Methadone | Participants will begin methadone during detention. Methadone: Interim methadone treatment (methadone without routine counseling) will be provided in jail. Methadone treatment with counseling will be continued in the community. |
| FG002 | Enhanced Treatment as Usual | Participants will receive opioid detoxification during detention, as well as drug abuse education, overdose prevention education, and referral to drug abuse treatment and overdose prevention services in the community. Enhanced Treatment as Usual (ETAU): Participants will receive methadone detoxification, drug abuse and overdose prevention information, drug treatment and overdose prevention referral in the community. |
| Title | Milestones | Reasons Not Completed | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Methadone Plus Patient Navigation | Participants will begin methadone treatment during detention and will have a patient navigator for up to 3 months post-release from detention. Methadone: Interim methadone treatment (methadone without routine counseling) will be provided in jail. Methadone treatment with counseling will be continued in the community. Patient Navigation: A patient navigator will assist the participant for the first three months after release from jail to enter and remain in methadone treatment in the community. |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Predicted Probability Derived From the Generalized Linear Mixed Model of Opioid Urine Test Positive Results Over Time | Predicted probability derived from the generalized linear mixed model opioid positive urine tests (0= negative; 1- positive) for heroin, oxycodone, methadone, or buprenorphine -- excluding the latter two positives when they results from prescribed medications to treat opioid use disorder) | The number analyzed at the follow-up points differ due to missing data (e.g., lost to follow-up, incarcerated individuals who were not drug tested, people interviewed by phone because they no longer lived in the area). | Posted | Least Squares Mean | Standard Error | Probability | 1, 3, 6, and 12 months post-release from incarceration |
|
12 months following release from index incarceration
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Methadone Plus Patient Navigation | Participants will begin methadone treatment during detention and will have a patient navigator for up to 3 months post-release from detention. Methadone: Interim methadone treatment (methadone without routine counseling) will be provided in jail. Methadone treatment with counseling will be continued in the community. Patient Navigation: A patient navigator will assist the participant for the first three months after release from jail to enter and remain in methadone treatment in the community. |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Hospitalization | Hepatobiliary disorders | Non-systematic Assessment |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Non fatal overdose | Injury, poisoning and procedural complications | Non-systematic Assessment |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Robert P. Schwartz, M.D. | Friends Research Institute | 410-837-3977 | 276 | rschwartz@friendsresearch.org |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan | Aug 9, 2018 | May 25, 2020 | Prot_SAP_000.pdf |
Not provided
| ID | Term |
|---|---|
| D009293 | Opioid-Related Disorders |
| ID | Term |
|---|---|
| D000079524 | Narcotic-Related Disorders |
| D019966 | Substance-Related Disorders |
| D064419 | Chemically-Induced Disorders |
| D001523 | Mental Disorders |
Not provided
Not provided
| ID | Term |
|---|---|
| D008691 | Methadone |
| D062526 | Patient Navigation |
| ID | Term |
|---|---|
| D007659 | Ketones |
| D009930 | Organic Chemicals |
| D018802 | Patient-Centered Care |
| D011320 | Primary Health Care |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Patient Navigation | Behavioral | A patient navigator will assist the participant for the first three months after release from jail to enter and remain in methadone treatment in the community. |
|
| Enhanced Treatment as Usual (ETAU) | Behavioral | Participants will receive methadone detoxification, drug abuse and overdose prevention information, drug treatment and overdose prevention referral in the community. |
|
| one month period prior to the 3, 6, and 12 month post-release from incarceration |
| Number of Participants With Arrests | Official data on participant arrests subsequent to release from index incarceration. | one year post-release from incarceration |
| Drug Risk Score on the Risk Assessment Battery (RAB) | Drug Risk Scale Score on the Risk Assessment Battery. The scale's range goes from 0 to 22. Higher score represents greater frequency of drug risk behaviors | Baseline and 6, and 12 months post-release from incarceration |
| Sex Risk Score on the Risk Assessment Battery (RAB) | Sex Risk Score on the Risk Assessment Battery (RAB). Higher scores represents greater risk. The score ranges from 0 to 18. | Baseline and 6, and 12 months post-release from incarceration |
| Physical Domain Score on the World Health Organization Quality of Life Scale (WHOQOL-BREF) | The score on the Physical Domain Scale of the World Health Organization Quality of Life Scale-BREF (WHOQOL-BREF). The scales range is from 0 to 100. The higher score represents better quality of life. | 1, 3, 6, and 12 months post-incarceration |
| Psychological Domain Score on the World Health Organization Quality of Life Scale (WHOQOL-BREF) | Scale score on the Psychological Domain on the World Health Organization Quality of Life Scale (WHOQOL-BREF) goes from 1 to 100. The higher score represents a better quality of life. | 1, 3, 6, and 12 months post-release from incarceration |
| Social Domain Score on the World Health Organization Quality of Life Scale (WHOQOL-BREF) | Social domain scale score on the World Health Organization Quality of Life Scale (WHOQOL-BREF) goes from 1 to 100. The higher score represents a better quality of life. | 1, 3, 6, and 12 month post-release from incarceration |
| Environmental Domain Score on the World Health Organization Quality of Life Scale (WHOQOL-BREF) | Environmental domain score on the World Health Organization Quality of Life Scale (WHOQOL-BREF) goes from 1 to 100. A higher score represents a better quality of life. | 1, 3, 6, and 12 months post-release from incarceration |
| Overall Quality of Life Score on the World Health Organization Quality of Life Scale (WHOQOL-BREF) | Self report quality of life as reported by participants following release from their index incarceration on a scale from 1 to 5. A higher score is a better outcome. | 1, 3, 6, and 12 month post-release from incarceration |
| Predicted Probability Derived From the Generalized Linear Mixed Model of Being Retained in Treatment for Opioid Use Disorder on the Methadone Treatment Exposure Form | Predicted Probability derived from the Generalized Linear Mixed of self-reported enrolled in treatment for Opioid Use Disorder at the time of the follow-up interview (0=not enrolled; 1=enrolled). | 12 months post-release from incarceration |
| Mean Number of Days of Criminal Activity in the Past 30 Days Reported by Participants on the Addiction Severity Index (ASI) | Mean number of days reported by participants of their criminal activity during the 30 days preceding the Addiction Severity Index interviews | 1, 3, 6, and 12 months post-release from incarceration |
| Mean Number of Days of Illicit Opioid Use Reported by Participants in the Past 30 Days | Mean number of participant self-reported days of heroin use in the 30 days preceding the interview on the Addiction Severity Index (ASI) | 1, 3, 6, and 12 months post-release from incarceration |
| Participant Self-reported Mean Number of Days of Cocaine Use in the Past 30 Days | Participant self-reported mean number of days of cocaine use in the 30 days preceding the interview on the Addiction Severity Index (ASI) | 1, 3, 6, and 12 months post-release from incarceration |
| Predicted Probability Derived From the Generalized Linear Mixed Model of Meeting Cocaine Use Disorder Criteria in the Past 30 Days | Predicted Probability Derived from the Generalized Linear Mixed Model meeting Data and Statistical Manual - 5 criteria for Cocaine Use Disorder on the modified Composite International Diagnostic Interview (CIDI) (0=Does not meet criteria; 1=meets criteria). | 3, 6, and 12 months post-release from incarceration |
| Days of Hospitalization (Health Care Utilization) on the Economic Form 90 (EF-90) | Mean number of days hospitalized during the 12 months post-release from incarceration | 12 months post-release from incarceration |
| Cost of Substance Abuse Services | Cost in US Dollars of substance abuse services on the modified Substance Abuse Services Cost Analysis Program | 12 months post-release from incarceration |
| 31748939 | Derived | Mitchell MM, Gryczynski J, Mitchell SG, Kelly SM, O'Grady KE, Monico LB, Schwartz RP. A Latent Class Analysis of HIV Risk Factors Among Men and Women with Opioid Use Disorder in Pre-trial Detention. AIDS Behav. 2020 Jun;24(6):1776-1783. doi: 10.1007/s10461-019-02726-y. |
| 27282117 | Derived | Schwartz RP, Kelly SM, Mitchell SG, Dunlap L, Zarkin GA, Sharma A, O'Grady KE, Jaffe JH. Interim methadone and patient navigation in jail: Rationale and design of a randomized clinical trial. Contemp Clin Trials. 2016 Jul;49:21-8. doi: 10.1016/j.cct.2016.06.002. Epub 2016 Jun 7. |
| Withdrawal by Subject |
|
| Not released from incarceration on time |
|
| Incarcerated |
|
| BG001 | Methadone | Participants will begin methadone during detention. Methadone: Interim methadone treatment (methadone without routine counseling) will be provided in jail. Methadone treatment with counseling will be continued in the community. |
| BG002 | Enhanced Treatment as Usual | Participants will receive opioid detoxification during detention, as well as drug abuse education, overdose prevention education, and referral to drug abuse treatment and overdose prevention services in the community. Enhanced Treatment as Usual (ETAU): Participants will receive methadone detoxification, drug abuse and overdose prevention information, drug treatment and overdose prevention referral in the community. |
| BG003 | Total | Total of all reporting groups |
| years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Ethnicity (NIH/OMB) | Count of Participants | Participants |
|
| Race (NIH/OMB) | Count of Participants | Participants |
|
| Region of Enrollment | Count of Participants | Participants |
|
| OG001 | Methadone | Participants will begin methadone during detention. Methadone: Interim methadone treatment (methadone without routine counseling) will be provided in jail. Methadone treatment with counseling will be continued in the community. |
| OG002 | Enhanced Treatment as Usual | Participants will receive opioid detoxification during detention, as well as drug abuse education, overdose prevention education, and referral to drug abuse treatment and overdose prevention services in the community. Enhanced Treatment as Usual (ETAU): Participants will receive methadone detoxification, drug abuse and overdose prevention information, drug treatment and overdose prevention referral in the community. |
|
|
|
| Primary | Predicted Probability Derived From the General Linear Mixed Model of Entry Into Treatment for Opioid Use Disorder on the Methadone Treatment Exposure Form | Predicted probability derived from the general linear mixed model of self-reported entry into treatment for opioid use disorder following release from incarceration and being in treatment 30 days post-release (0= no entry in treatment; 1= entry in treatment). | Posted | Least Squares Mean | Standard Error | Probability | 30 days post-release from incarceration |
|
|
|
|
| Secondary | Predicted Probability Derived From Generalized Linear Mixed Model of Meeting Opioid Use Disorder Criteria as Determined by the Modified Composite International Diagnostic Interview (CIDI) | Predicted probability derived from the Generalized Linear Mixed Model of meeting the Data and Statistical Manual - 5 criteria for Opioid Use Disorder in response to modified CIDI interview (0= does not meet criteria; 1= meets criteria). | The number analyzed at the follow-up points differ due to missing data (e.g., lost to follow-up, people who were incarcerated during the 30 days prior to the interview). | Posted | Least Squares Mean | Standard Error | Probability | one month period prior to the 3, 6, and 12 month post-release from incarceration |
|
|
|
|
| Secondary | Number of Participants With Arrests | Official data on participant arrests subsequent to release from index incarceration. | Data presented on the subset of those participants who were released from index incarceration during the study. | Posted | Count of Participants | Participants | one year post-release from incarceration |
|
|
|
|
| Secondary | Drug Risk Score on the Risk Assessment Battery (RAB) | Drug Risk Scale Score on the Risk Assessment Battery. The scale's range goes from 0 to 22. Higher score represents greater frequency of drug risk behaviors | The number analyzed at the follow-up points differ due to missing data (e.g., lost to follow-up, people who were incarcerated during the 6 months prior to the interview). | Posted | Least Squares Mean | Standard Error | score on a scale | Baseline and 6, and 12 months post-release from incarceration |
|
|
|
|
| Secondary | Sex Risk Score on the Risk Assessment Battery (RAB) | Sex Risk Score on the Risk Assessment Battery (RAB). Higher scores represents greater risk. The score ranges from 0 to 18. | The number analyzed at the follow-up points differ due to missing data (e.g., lost to follow-up, people who were incarcerated during the 6 months prior to the interview). | Posted | Least Squares Mean | Standard Error | score on a scale | Baseline and 6, and 12 months post-release from incarceration |
|
|
|
|
| Secondary | Physical Domain Score on the World Health Organization Quality of Life Scale (WHOQOL-BREF) | The score on the Physical Domain Scale of the World Health Organization Quality of Life Scale-BREF (WHOQOL-BREF). The scales range is from 0 to 100. The higher score represents better quality of life. | The number analyzed at the follow-up points differ due to missing data (e.g., lost to follow-up, people who were incarcerated during the 4 weeks prior to the interview). | Posted | Least Squares Mean | Standard Error | score on a scale | 1, 3, 6, and 12 months post-incarceration |
|
|
|
|
| Secondary | Psychological Domain Score on the World Health Organization Quality of Life Scale (WHOQOL-BREF) | Scale score on the Psychological Domain on the World Health Organization Quality of Life Scale (WHOQOL-BREF) goes from 1 to 100. The higher score represents a better quality of life. | The number analyzed at the follow-up points differ due to missing data (e.g., lost to follow-up, people who were incarcerated during the 4 weeks prior to the interview). | Posted | Least Squares Mean | Standard Error | score on a scale | 1, 3, 6, and 12 months post-release from incarceration |
|
|
|
|
| Secondary | Social Domain Score on the World Health Organization Quality of Life Scale (WHOQOL-BREF) | Social domain scale score on the World Health Organization Quality of Life Scale (WHOQOL-BREF) goes from 1 to 100. The higher score represents a better quality of life. | The number analyzed at the follow-up points differ due to missing data (e.g., lost to follow-up, people who were incarcerated during the 4 weeks prior to the interview). | Posted | Least Squares Mean | Standard Error | score on a scale | 1, 3, 6, and 12 month post-release from incarceration |
|
|
|
|
| Secondary | Environmental Domain Score on the World Health Organization Quality of Life Scale (WHOQOL-BREF) | Environmental domain score on the World Health Organization Quality of Life Scale (WHOQOL-BREF) goes from 1 to 100. A higher score represents a better quality of life. | The number analyzed at the follow-up points differ due to missing data (e.g., lost to follow-up, people who were incarcerated during the 4 weeks prior to the interview). | Posted | Least Squares Mean | Standard Error | score on a scale | 1, 3, 6, and 12 months post-release from incarceration |
|
|
|
|
| Secondary | Overall Quality of Life Score on the World Health Organization Quality of Life Scale (WHOQOL-BREF) | Self report quality of life as reported by participants following release from their index incarceration on a scale from 1 to 5. A higher score is a better outcome. | The number analyzed at the follow-up points differ due to missing data (e.g., lost to follow-up, people who were incarcerated during the 4 weeks prior to the interview). | Posted | Least Squares Mean | Standard Error | units on a scale | 1, 3, 6, and 12 month post-release from incarceration |
|
|
|
|
| Secondary | Predicted Probability Derived From the Generalized Linear Mixed Model of Being Retained in Treatment for Opioid Use Disorder on the Methadone Treatment Exposure Form | Predicted Probability derived from the Generalized Linear Mixed of self-reported enrolled in treatment for Opioid Use Disorder at the time of the follow-up interview (0=not enrolled; 1=enrolled). | Participants who had completed at least one follow-up interview. | Posted | Least Squares Mean | Standard Error | Probability | 12 months post-release from incarceration |
|
|
|
|
| Secondary | Mean Number of Days of Criminal Activity in the Past 30 Days Reported by Participants on the Addiction Severity Index (ASI) | Mean number of days reported by participants of their criminal activity during the 30 days preceding the Addiction Severity Index interviews | Participants who completed at least one follow-up interview following release from index incarceration | Posted | Least Squares Mean | Standard Error | Days | 1, 3, 6, and 12 months post-release from incarceration |
|
|
|
|
| Secondary | Mean Number of Days of Illicit Opioid Use Reported by Participants in the Past 30 Days | Mean number of participant self-reported days of heroin use in the 30 days preceding the interview on the Addiction Severity Index (ASI) | Participants who were interviewed at least once following release from index incarceration. | Posted | Least Squares Mean | Standard Error | Days | 1, 3, 6, and 12 months post-release from incarceration |
|
|
|
|
| Secondary | Participant Self-reported Mean Number of Days of Cocaine Use in the Past 30 Days | Participant self-reported mean number of days of cocaine use in the 30 days preceding the interview on the Addiction Severity Index (ASI) | Participants who were interviewed at least once following release from index incarceration | Posted | Least Squares Mean | Standard Error | Days | 1, 3, 6, and 12 months post-release from incarceration |
|
|
|
|
| Secondary | Predicted Probability Derived From the Generalized Linear Mixed Model of Meeting Cocaine Use Disorder Criteria in the Past 30 Days | Predicted Probability Derived from the Generalized Linear Mixed Model meeting Data and Statistical Manual - 5 criteria for Cocaine Use Disorder on the modified Composite International Diagnostic Interview (CIDI) (0=Does not meet criteria; 1=meets criteria). | Participants who completed at least one interview following release from index incarceration | Posted | Least Squares Mean | Standard Error | Probability | 3, 6, and 12 months post-release from incarceration |
|
|
|
|
| Secondary | Days of Hospitalization (Health Care Utilization) on the Economic Form 90 (EF-90) | Mean number of days hospitalized during the 12 months post-release from incarceration | Posted | Mean | Standard Deviation | Days | 12 months post-release from incarceration |
|
|
|
| Secondary | Cost of Substance Abuse Services | Cost in US Dollars of substance abuse services on the modified Substance Abuse Services Cost Analysis Program | Posted | Mean | Standard Deviation | US Dollars | 12 months post-release from incarceration |
|
|
|
| 1 |
| 75 |
| 11 |
| 75 |
| 3 |
| 75 |
| EG001 | Methadone | Participants will begin methadone during detention. Methadone: Interim methadone treatment (methadone without routine counseling) will be provided in jail. Methadone treatment with counseling will be continued in the community. | 3 | 74 | 20 | 74 | 12 | 74 |
| EG002 | Enhanced Treatment as Usual | Participants will receive opioid detoxification during detention, as well as drug abuse education, overdose prevention education, and referral to drug abuse treatment and overdose prevention services in the community. Enhanced Treatment as Usual (ETAU): Participants will receive methadone detoxification, drug abuse and overdose prevention information, drug treatment and overdose prevention referral in the community. | 3 | 76 | 16 | 76 | 12 | 76 |
| Hospitalization | Infections and infestations | Non-systematic Assessment |
|
| Hospitalization | Injury, poisoning and procedural complications | Non-systematic Assessment |
|
| Hospitalization | Musculoskeletal and connective tissue disorders | Non-systematic Assessment |
|
| Hospitalization | Psychiatric disorders | Non-systematic Assessment |
|
| Hospitalization | Respiratory, thoracic and mediastinal disorders | Non-systematic Assessment |
|
| Hospitalization | Gastrointestinal disorders | Non-systematic Assessment |
|
| Hospitalization | Nervous system disorders | Non-systematic Assessment |
|
| Hospitalization | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Non-systematic Assessment |
|
| Hospitalization | Vascular disorders | Non-systematic Assessment |
|
| Hospitalization | Blood and lymphatic system disorders | Non-systematic Assessment |
|
| Hospitalization | Cardiac disorders | Non-systematic Assessment |
|
| Hospitalization | Metabolism and nutrition disorders | Non-systematic Assessment |
|
Not provided
Not provided
| D003191 |
| Comprehensive Health Care |
| D010346 | Patient Care Management |
| D006298 | Health Services Administration |
| Generalized Linear Mixed Model Analysis |
| .84 |
| Superiority |
| 6 months post-release from incarceration |
|
|
| 12 months post-release from incarceration |
|
|
| Generalized Linear Mixed Model Analysis |
| 0.55 |
| Superiority |
| 0.57 |
| Superiority |
| 6 month post-release from incarceration |
|
|
| 12 month post-release |
|
|
| Generalized Linear Mixed Model Analysis |
| 0.26 |
| Superiority |
| 6 months post-release |
|
|
| 12 month post-release |
|
|
| Generalized Linear Mixed Model Analysis |
| 0.33 |
| Superiority |
| 1 months post-release from incarceration |
|
|
| 3 months post-release from incarceration |
|
|
| 6 months post-release from incarceration |
|
|
| 12 months post-release from incarceration |
|
|
| Generalized Linear Mixed Model Analysis |
| .76 |
| Superiority |
| 1 month post-release from incarceration |
|
|
| 3 months post-release from incarceration |
|
|
| 6 months post-release from incarceration |
|
|
| 12 months post-release from incarceration |
|
|
| Generalized Linear Mixed Model Analysis |
| 1.0 |
| Superiority |
| 1 month post-release from incarceration |
|
|
| 3 months post-release from incarceration |
|
|
| 6 months post-release from incarceration |
|
|
| 12 months post-release from incarceration |
|
|
| Generalized Linear Mixed Model Analysis |
| .74 |
| Superiority |
| 1 months post-release from incarceration |
|
|
| 3 months post-release from incarceration |
|
|
| 6 months post-release from incarceration |
|
|
| 12 months post-release from incarceration |
|
|
| Generalized Linear Mixed Model Analysis |
| .71 |
| Superiority |
| 1 month post-release from incarceration |
|
|
| 3 months post-release from incarceration |
|
|
| 6 months post-release from incarceration |
|
|
| 12 months post-release from incarceration |
|
|
| Generalized Linear Mixed Model Analysis |
| 0.85 |
| Superiority |
| 3 months post-release from incarceration |
|
|
| 6 months post-release from incarceration |
|
|
| 12 months post-release from incarceration |
|
|
| Generalized Linear Mixed Model Analysis |
| .74 |
| Superiority |
| 3 months post-release from incarceration |
|
|
| 6 months post-release from incarceration |
|
|
| 12 months post-release from incarceration |
|
|
| Generalized Linear Mixed Model Analysis |
| 0.42 |
| Superiority |
| 3 months post-release from incarceration |
|
|
| 6 months post-release from incarceration |
|
|
| 12 months post-release from incarceration |
|
|
| Generalized Linear Mixed Model Analysis |
| 0.44 |
| Superiority |
| 3 months post-release from incarceration |
|
|
| 6 months post-release from incarceration |
|
|
| 12 months post-release from incarceration |
|
|
| Generalized Linear Mixed Model Analysis |
| 0.72 |
| Superiority |
| 6 months post-release from incarceration |
|
|
| 12 months post-release from incarceration |
|
|
| Generalized Linear Mixed Model Analysis |
| .86 |
| Superiority |